ProCE Banner Activity

My Perspective on the Recent Approval of Niraparib as First-line Maintenance Therapy in Ovarian Cancer and the Clinical Implications

Clinical Thought

Now that niraparib is approved in the first-line maintenance therapy setting, how will your treatment of patients with ovarian cancer change?

This educational activity is intended for clinicians practicing medicine outside of the United States.

Released: January 11, 2021

Expiration: January 10, 2022

No longer available for credit.

Share

Faculty

Ursula Matulonis

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ursula Matulonis, MD, has disclosed that she has received consulting fees and other financial or material support from Merck.